Literature DB >> 6090374

Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals.

N Klesel, M Limbert, K Seeger, G Seibert, I Winkler, E Schrinner.   

Abstract

The pharmacokinetic properties of cefodizime, a new aminothiazolyliminomethoxycephalosporin, were studied in laboratory animals and compared with the pharmacokinetics of another long-acting cephalosporin, ceftriaxone. Both cephalosporin derivatives showed high affinity (33-99%) for serum proteins. High and prolonged blood respectively serum levels of the antibiotics were achieved following subcutaneous and intravenous injection into mice, rats, rabbits, dogs and monkeys. Cefodizime elimination half-lives ranged from 1.17 hours in mice to 3.53 hours in rabbits compared to ceftriaxone half-lives ranging from 0.73 hour in mice to 7.31 hours in rabbits. The antibiotics were well distributed in the body and penetrated into tissues and body fluids to a high degree. Particularly high and prolonged levels were detected in the lungs, liver and kidneys of the experimental animals. Large amounts, approximately 35-55% of the given dose, were recovered in the urine of rabbits and dogs, while the recovery rate in the bile of rabbits was only 0.57% for cefodizime and 1.08% for ceftriaxone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090374     DOI: 10.7164/antibiotics.37.901

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  9 in total

1.  Pharmacokinetics and dosage regimen of ceftriaxone in buffalo calves.

Authors:  M S Dardi; S K Sharma; A K Srivastava
Journal:  Vet Res Commun       Date:  2004-05       Impact factor: 2.459

2.  Effect of protein binding in serum on therapeutic efficacy of cephem antibiotics.

Authors:  S Tawara; S Matsumoto; T Kamimura; S Goto
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  In vivo activity of cefodizime.

Authors:  P M Shah; H Knothe
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 4.  Pharmacokinetic profile of cefodizime.

Authors:  D Brockmeier; E E Dagrosa
Journal:  Infection       Date:  1992       Impact factor: 3.553

Review 5.  In vitro activity of cefodizime.

Authors:  H Knothe; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

6.  Influence of cefodizime on the reagibility of human leukocytes.

Authors:  M Limbert; H Müllner; P M Shah
Journal:  Infection       Date:  1992       Impact factor: 3.553

7.  Cefodizime penetration into skin suction blister fluid following a single intravenous dose.

Authors:  M Schäfer-Korting; H C Korting; L Maass; N Klesel; H G Grigoleit; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Characterizing ceftriaxone-induced urolithiasis and its associated acute kidney injury: an animal study and Chinese clinical systematic review.

Authors:  Yifan Zhang; Benxiang Ning; Huaijun Zhu; Xiaoming Cong; Leqing Zhou; Qiang Wang; Liming Zhang; Xizhao Sun
Journal:  Int Urol Nephrol       Date:  2016-04-28       Impact factor: 2.370

9.  Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.

Authors:  N Klesel; M Limbert; G Seibert; I Winkler; E Schrinner
Journal:  Infection       Date:  1986       Impact factor: 3.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.